ProShare Advisors
ZNTL icon

ProShare Advisors’s Zentalis Pharmaceuticals ZNTL Stock Holding History

ProShare Advisors’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,370
Closed -$19.7K – 2199
2025
Q1 		$19.7K Sell
12,370
-3,724
-23% -$8.03K ﹤0.01% 2038
2024
Q4 		$48.8K Sell
16,094
-13,904
-46% -$45.6K ﹤0.01% 2179
2024
Q3 		$110K Buy
29,998
+17,814
+146% +$64.7K ﹤0.01% 1863
2024
Q2 		$49.8K Sell
12,184
-3,252
-21% -$36.3K ﹤0.01% 1751
2024
Q1 		$243K Buy
15,436
+1,274
+9% +$17.5K ﹤0.01% 1552
2023
Q4 		$215K Buy
14,162
+1,979
+16% +$28.9K ﹤0.01% 1598
2023
Q3 		$244K Buy
12,183
+1,946
+19% +$49.4K ﹤0.01% 1339
2023
Q2 		$289K Buy
+10,237
New +$246K ﹤0.01% 1299
2023
Q1 		– Sell
-10,759
Closed -$217K – 1925
2022
Q4 		$217K Buy
10,759
+791
+8% +$17K ﹤0.01% 1443
2022
Q3 		$217K Buy
9,968
+1,230
+14% +$33.6K ﹤0.01% 1356
2022
Q2 		$245K Sell
8,738
-2,818
-24% -$74.6K ﹤0.01% 1337
2022
Q1 		$534K Sell
11,556
-2,794
-19% -$151K ﹤0.01% 1248
2021
Q4 		$1.21M Buy
14,350
+132
+0.9% +$10.2K ﹤0.01% 937
2021
Q3 		$947K Sell
14,218
-1,830
-11% -$106K ﹤0.01% 926
2021
Q2 		$854K Buy
16,048
+2,745
+21% +$147K ﹤0.01% 1124
2021
Q1 		$577K Buy
13,303
+665
+5% +$28.6K ﹤0.01% 1340
2020
Q4 		$656K Buy
+12,638
New +$570K ﹤0.01% 1097

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

ProShare Advisors's ZNTL Position: Q2 2025 in Review

ProShare Advisors sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2025, closing a stake of 12,370 shares — an estimated $19.7K sold.

ProShare Advisors first reported a position in ZNTL in Q4 2020 and held it in 17 quarters. The position peaked at $1.21M in Q4 2021. 117 funds tracked by Wall St. Rank hold ZNTL as of Q2 2025.

  • ProShare Advisors reported no remaining Zentalis Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • ProShare Advisors sold 12,370 Zentalis Pharmaceuticals shares in Q2 2025, an estimated $19.7K.
  • ProShare Advisors first reported a position in Zentalis Pharmaceuticals in Q4 2020 and held it in 17 quarters.
  • ProShare Advisors's Zentalis Pharmaceuticals position peaked at $1.21M in Q4 2021.
  • 117 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2025.

Based on ProShare Advisors's 13F filing for Q2 2025, filed 7 Aug 2025.